Читать книгу Recent Advances in Dialysis Therapy in Japan - Группа авторов - Страница 76

1Yoshimitsu T, Hirakata H, Fujii K, et al: Cerebral ischemia as a causative mechanism for rapid progression of brain atrophy in chronic hemodialysis patients. Clin Nephrol 2000;53:445–451.

2Taki Y, Goto R, Evans A, et al: Voxel-based morphometry of human brain with age and cerebrovascular risk factors. Neurobiol Aging 2004;25:455–463.

3Tsuruya K, Yoshida H, Kuroki Y, et al: Brain atrophy in peritoneal dialysis and CKD stages 3–5: a cross-sectional and longitudinal study. Am J Kidney Dis 2015;65:312–321.

4Tsuruya K, Yoshida H, Haruyama N, et al: Clinical significance of fronto-temporal gray matter atrophy in executive dysfunction in patients with chronic kidney disease: the VCOHP Study. PLoS One 2015;10:e0143706.

5Pereira AA, Weiner DE, Scott T, et al: Cognitive function in dialysis patients. Am J Kidney Dis 2005;45:448–462.

6Hirakata H, Yao H, Osato S, et al: CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO. Am J Physiol 1992;262:F737–743.

7Kanai H, Hirakata H, Nakane H, et al: Depressed cerebral oxygen metabolism in patients with chronic renal failure: a positron emission tomography study. Am J Kidney Dis 2001;38:S129–S133.

8Kuwabara Y, Sasaki M, Hirakata H, et al: Cerebral blood flow and vasodilatory capacity in anemia secondary to chronic renal failure. Kidney Int 2002;61:564–569.

9Temple RM, Langan SJ, Deary IJ, Winney RJ: Recombinant erythropoietin improves cognitive function in chronic haemodialysis patients. Nephrol Dial Transplant 1992;7:240–245.

10Grimm G, Stockenhuber F, Schneeweiss B, Madl C, Zeitlhofer J, Schneider B: Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int 1990;38:480–486.

11Hirakata H, Kanai H, Fukuda K, et al: Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients. Clin Nephrol 2000;53:354–361.

12Wolfgram DF, Szabo A, Murray AM, Whittle J: Risk of dementia in peritoneal dialysis patients compared with hemodialysis patients. Perit Dial Int 2015;35:189–198.

13O’Lone E, Connors M, Masson P, et al: Cognition in people with end-stage kidney disease treated with hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis 2015;67:925–935.

14Ok E, Duman S, Asci G, et al: Comparison of 4- and 8-h dialysis sessions in thrice-weekly in-centre haemodialysis: a prospective, case-controlled study. Nephrol Dial Transplant 2011;26:1287–1296.

15FHN Trial Group: In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010;363:2287–2300.

16Takae K, Hata J, Ohara T, et al: Albuminuria increases the risks for both Alzheimer’s disease and vascular dementia in community-dwelling Japanese elderly: the Hisayama Study. J Am Heart Assoc 2018;7:e006693.

17Fujisaki K, Tsuruya K, Yamato M, et al: Cerebral oxidative stress induces spatial working memory dysfunction in uremic mice: neuroprotective effect of tempol. Nephrol Dial Transplant 2014;9:529–538.

18Haruyama N, Fujisaki K, Yamato M, et al: Improvement in spatial memory dysfunction by telmisartan through reduction of brain angiotensin II and oxidative stress in experimental uremic mice. Life Sci 2014;113:55–59.

19Zhuang S, Wang HF, Wang X, et al: The association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer’s disease: a meta-analysis. J Clin Neurosci 2016;33:32–38.

Kazuhiko Tsuruya, MD, PhD

Department of Nephrology, Nara Medical University

840 Shijocho, Kashihara, 634-8521 Nara (Japan)

E-Mail tsuruya@naramed-u.ac.jp